BMO Capital Raises Merck Price Target to $170

Merck's price target has been raised to $170 from $142 by BMO Capital, according to TipRanks.

The increase is based on backtested results, which have inherent limitations and may not reflect actual trading or the effect of material economic and market factors.

The backtested performance shows that if a strategy had been followed, it would have resulted in certain returns. However, these results are adjusted to reflect the reinvestment of dividends and do not include the effect of backtested transaction costs, management fees, performance fees or expenses.